Quibim Secures $50 Million in Series A Financing
Quibim, a healthtech innovator based in Spain, has recently successfully concluded its Series A financing round, securing $50 million to enhance the development of AI-powered imaging biomarkers for precision medicine. Esteemed investors, including Asabys and Buenavista Equity Partners, led this financing initiative, which aims to transform healthcare by leveraging innovative imaging technologies.
Growth and Expansion Strategies
Over the past year, Quibim has substantiated its growth trajectory by analyzing an increasing number of patients with its cutting-edge products. The surge in patient analysis stands at an impressive 168% quarter-on-quarter, attributed to the company’s expanding global partnerships and regulatory approvals. This newfound capital will further bolster Quibim’s efforts to establish a robust presence in the United States while consolidating its success in Europe.
Realizing the Vision of Digital Twins
Quibim's mission transcends mere patient analysis. The company aspires to develop highly detailed, non-invasive models of human anatomy based on imaging data. These digital twins aim to provide comprehensive insights at the organ and lesion level, promising improved patient stratification, accelerated drug development, and enhanced monitoring of health outcomes. With solutions like QP-Brain, QP-Prostate, and QP-Liver, Quibim is making strides in transforming how patients are evaluated and treated across various disciplines, such as oncology and neurology.
Applications of AI in Imaging
— By employing advanced AI techniques, Quibim can extract meaningful insights from popular imaging modalities including MRI, CT, and PET scans. The capacity to characterize phenotypes accurately and predict potential health outcomes exemplifies the immense benefits of integrating these technologies into clinical workflows. As the volume of actionable data grows, Quibim is poised to analyze holistic scans that span entire bodies, thereby refining and revolutionizing diagnostics.
Strengthening Collaborations with Biopharma Partners
Quibim has forged impactful partnerships with prestigious healthcare institutions and biopharma companies, consolidating its presence in the medical community. With over 170 installations across globally recognized entities such as Mass General Brigham and Stanford, Quibim’s cutting-edge technology underlines its commitment to bridging research, clinical applications, and drug development. Noteworthy collaborations, including a global partnership with Philips, highlight the integration of AI models with MRI scanners, enhancing diagnostic capabilities.
Commitment to Precision Health
"At Quibim, we are profoundly dedicated to revolutionizing how imaging catalyzes precision health," stated Dr. Ángel Alberich-Bayarri, the company's CEO. He expressed gratitude to both new and existing investors, recognizing their pivotal role as Quibim embarks on a significant U.S. expansion. This expansion enables the company to collaborate closely with healthcare providers and pharmaceutical leaders, ensuring the transformative potential of imaging is fully realized for patient benefit.
Robust Product Portfolio
Quibim continues to enhance its product portfolio, which includes:
- QP-Prostate: This flagship product reinforces prostate cancer detection using advanced AI algorithms. It is CE, UKCA marked, and 510(k) cleared.
- QP-Brain: Focused on early-stage neurological disease quantification, it helps evaluate brain atrophy and lesion analysis.
- QP-Liver: A tool that automates MR diagnoses related to liver disease, providing precise quantification of tissue fat and iron levels.
- QP-Insights: A platform designed to manage and analyze extensive multi-omics data effectively, contributing significantly to clinical trials and real-world studies.
Quibim's strategic focus involves enhancing its existing solutions while actively building collaborative relationships with hospitals and pharmaceutical firms. This proactive approach will enable the processing of vast medical data, facilitating improved patient outcomes and clinical efficiencies.
Industry Recognition and Future Outlook
Guillem Masferrer from Asabys Partners emphasizes the importance of Quibim's innovative solutions in meeting critical needs in healthcare sectors like oncology and neurology. As Quibim advances its technology, particularly with partnerships with leading pharmaceutical companies, a tremendous potential for growth and widespread impact is on the horizon. Quibim continues to pioneer the integration of radiomics and deep learning in imaging analysis, ensuring they remain at the forefront of industry innovation.
Frequently Asked Questions
What is Quibim's mission?
Quibim’s mission is to enhance patient outcomes through the innovative use of imaging biomarkers in precision medicine.
How much funding did Quibim secure?
Quibim completed a $50 million Series A financing round, led by notable investors including Asabys and Buenavista Equity Partners.
What products does Quibim offer?
Quibim’s product offerings include QP-Prostate, QP-Brain, QP-Liver, and QP-Insights, each aimed at improving diagnostic accuracy and patient care.
Where is Quibim expanding its presence?
Quibim is establishing a stronger presence in the U.S. while continuing to build on its success in Europe.
What technologies does Quibim utilize?
Quibim employs AI techniques to analyze imaging data from MRI, CT, and PET scans to extract actionable insights for healthcare professionals.
